Related Experiment Video

Updated: Aug 4, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Clinical use of the new macrolides, azalides, and streptogramins in pediatrics

D Adam1

  • 1Children's Hospital, University of Munich, Germany.

Journal of Chemotherapy (Florence, Italy)
|December 1, 1992
PubMed

Insights

Newer macrolides offer effective pediatric infection treatment with improved dosing and safety profiles. These antibiotics show good tissue penetration and activity against various bacteria, making them valuable in pediatric care.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Macrolides are essential antibiotics for treating numerous pediatric infections.
  • Recent advancements have introduced newer macrolide agents with potentially improved characteristics.

Purpose of the Study:

  • To review the clinical applications of newer macrolides in pediatric infections.
  • To evaluate the efficacy, safety, and dosing of these agents in children.

Main Methods:

  • Review of clinical data and studies on newer macrolides.
  • Analysis of therapeutic uses in various pediatric bacterial and atypical infections.
  • Assessment of adverse event profiles and dosage regimens.

Main Results:

  • Newer macrolides demonstrate efficacy against streptococcal, staphylococcal, mycoplasma, chlamydial, legionella, and campylobacter infections in children.
  • Advantages include lower doses, convenient once or twice-daily administration, and good tissue penetration.
  • Some agents show enhanced activity against certain gram-negative bacteria with a low incidence of adverse reactions.

Conclusions:

  • Newer macrolides represent a valuable therapeutic option for pediatric infections.
  • Their favorable pharmacokinetic and safety profiles support their use in pediatric populations.
  • Continued research and clinical experience will further define their role in pediatric infectious disease management.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...